Inflammatory bowel disease (IBD) is a frequently occurring disease that seriously influences
the patient's quality of life. To decrease adverse effects and improve efficacy of therapeutics …

pH-Responsive nanotherapeutics were recently developed for the treatment of ulcerative
colitis (UC). However, they target the entire colon rather than the UC site, which leads to …

Purpose Conventional oral formulations for inflammatory bowel disease (IBD) treatment are
less than satisfactory, due to the poor controllability of drug release and lack of specificity to …

Ulcerative colitis (UC) is a chronic or relapsing inflammatory disease with limited therapeutic
outcomes. Pterostilbene (PSB) is a polyphenol-based anti-oxidant that has received …

Oxidative stress and abnormally high levels of reactive oxygen species (ROS) play an
essential role in the pathogenesis and progression of inflammatory bowel disease (IBD) …

Dysregulated mucosal immune responses and colonic fibrosis impose two formidable
challenges for ulcerative colitis treatment. It indicates that monotherapy could not sufficiently …

Polyhydroxybutyrate (PHB) has emerged as a novel material for replacing various plastics
used in the medical field. However, its application as a drug-delivery carrier for colitis …

Background The oral administration of drugs for treating ulcerative colitis (UC) is hindered
by several factors, including inadequate gastrointestinal stability, insufficient accumulation in …

Background Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) of
unknown aetiology affecting the colon and rectum. Pterostilbene (PS) has been reported as …

Ulcerative colitis (UC) is a chronic inflammatory illness affecting the colon and rectum, with
current treatment methods being unable to meet the clinical needs of ulcerative colitis …